前脑啡肽A 119-159预测急性肾损伤危重患者早期成功脱离肾脏替代治疗:ELAIN试验的事后分析
该研究为ELAIN随机临床试验的事后分析,纳入210例肾脏替代治疗依赖的急性肾损伤危重患者,检测血前脑啡肽A 119-159(penKid)水平,采用竞争风险时间-事件分析。结果显示,启动肾脏替代治疗时penKid≤89 pmol/l的患者相比高penKid患者,28天成功脱离肾脏替代治疗累积发生率更高(61% vs 45%,p=0.022),亚分布风险比1.83(95%CI 1.26-2.67,p=0.002)。该关联在启动肾脏替代治疗第3天标志点分析中持续存在(67% vs 47%,p=0.018;sHR 1.78,95%CI 1.17-2.71,p=0.007)。两个时间点竞争事件死亡均无差异。作者认为penKid似乎是有用的生物标志物,可能有助于个体化指导肾脏替代治疗脱离策略。
要点
- 启动肾脏替代治疗时penKid≤89 pmol/l与28天成功脱离肾脏替代治疗累积发生率更高相关(61% vs 45%,p=0.022;sHR 1.83,95%CI 1.26-2.67,p=0.002)。
- 启动肾脏替代治疗第3天标志点分析中,penKid≤89 pmol/l组28天成功脱离累积发生率67% vs 47%(p=0.018;sHR 1.78,95%CI 1.17-2.71,p=0.007)。
- 两个时间点竞争事件死亡均无差异。
- 作者认为血浆penKid似乎是有用的生物标志物,可预测更短的肾脏替代治疗持续时间和成功脱离。
- 该分析为ELAIN试验的事后分析,纳入210例肾脏替代治疗依赖的急性肾损伤危重患者。
适用人群与场景
- ELAIN随机临床试验中的210例肾脏替代治疗依赖的急性肾损伤危重患者。
诊断标准与关键阈值
- 启动肾脏替代治疗时penKid≤89 pmol/l定义为低penKid水平。
研究设计与关键结果
- 研究类型:ELAIN随机临床试验的事后分析,纳入210例患者,检测血penKid水平,采用竞争风险时间-事件分析。
- 启动肾脏替代治疗时penKid≤89 pmol/l组相比高penKid组,28天成功脱离肾脏替代治疗累积发生率61% vs 45%(p=0.022),亚分布风险比1.83(95%CI 1.26-2.67,p=0.002)。
- 启动肾脏替代治疗第3天标志点分析中,penKid≤89 pmol/l组相比高penKid组,28天成功脱离累积发生率67% vs 47%(p=0.018),亚分布风险比1.78(95%CI 1.17-2.71,p=0.007)。
- 两个时间点竞争事件死亡均无差异。
证据类型、等级与局限
- 证据类型:随机临床试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血浆penKid似乎是有用的生物标志物,可预测更短的肾脏替代治疗持续时间和成功脱离,并可能有助于个体化指导肾脏替代治疗脱离策略。
指南或共识出处
- ELAIN试验(德国临床 trials 注册中心,注册号DRKS00004367,2013年5月28日注册)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Renal replacement therapy (RRT) remains the key rescue therapy for critically ill patients with severe acute kidney injury (AKI). However, there are currently no tools available to predict successful liberation from RRT. Biomarkers may allow for risk stratification and individualization of treatment strategies. Proenkephalin A 119-159 (penKid) has been suggested as a promising marker of kidney function in the context of AKI, but has not yet been evaluated for RRT liberation in critically ill patients with AKI.
METHODS: This post hoc analysis included 210 patients from the randomized clinical ELAIN trial and penKid levels were measured in the blood of these patients. Competing risk time-to-event analyses were performed for pre-RRT penKid at initiation of RRT and in a landmark analysis at day 3 after initiation of RRT. Competing risk endpoints were successful liberation from RRT or death without prior liberation from RRT.
RESULTS: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l) at RRT initiation were associated with early and successful liberation from RRT compared to patients with high pre-RRT penKid levels (subdistribution hazard ratio (sHR) 1.83, 95%CI 1.26-2.67, p = 0.002, estimated 28d-cumulative incidence function (28d-CIF) of successful liberation from RRT 61% vs. 45%, p = 0.022). This association persisted in the landmark analysis on day 3 of RRT (sHR 1.78, 95%CI 1.17-2.71, p = 0.007, 28d-CIF of successful liberation from RRT 67% vs. 47%, p = 0.018). For both time points, no difference in the competing event of death was detected.
CONCLUSIONS: In critically ill patients with RRT-dependent AKI, plasma penKid appears to be a useful biomarker for the prediction of shorter duration and successful liberation from RRT and may allow an individualized approach to guide strategies of RRT liberation in critically ill patients with RRT-dependent AKI.
TRIAL REGISTRATION: The ELAIN trial was prospectively registered at the German Clinical Trial Registry (Identifier: DRKS00004367) on 28th of May 2013.
参考来源
- von Groote T, Albert F, Meersch M, et al. Proenkephalin A 119-159 predicts early and successful liberation from renal replacement therapy in critically ill patients with acute kidney injury: a post hoc analysis of the ELAIN trial. Crit Care. 2022. PMID: 36316692. doi:10.1186/s13054-022-04217-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。